quinuclidines has been researched along with glycolipids in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashe, KM; Bangari, DS; Budman, E; Cheng, SH; Desnick, RJ; Leonard, JP; Marshall, J; Nietupski, JB; Scheule, RK; Siegel, CS; Wang, B | 1 |
| Allaire, A; Bangari, DS; Budman, E; Cheng, SH; Cromwell, MA; Grabowski, GA; Leonard, JP; Marshall, J; Nietupski, JB; Park, H; Sun, Y; Wang, B | 1 |
2 other study(ies) available for quinuclidines and glycolipids
| Article | Year |
|---|---|
Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.
Topics: alpha-Galactosidase; Animals; Blood-Brain Barrier; Carbamates; Disease Models, Animal; Fabry Disease; Glucosyltransferases; Glycolipids; Humans; Mice; Quinuclidines; Sphingolipids; Trihexosylceramides | 2015 |
CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.
Topics: Administration, Oral; Animals; Carbamates; Central Nervous System; Disease Models, Animal; Enzyme Inhibitors; Gaucher Disease; Glucosyltransferases; Glycolipids; Humans; Inositol; Liver; Lysosomes; Mice; Quinuclidines; Tissue Distribution; Treatment Outcome | 2016 |